395 related articles for article (PubMed ID: 24553122)
1. Acquired resistance to metformin in breast cancer cells triggers transcriptome reprogramming toward a degradome-related metastatic stem-like profile.
Oliveras-Ferraros C; Vazquez-Martin A; Cuyàs E; Corominas-Faja B; Rodríguez-Gallego E; Fernández-Arroyo S; Martin-Castillo B; Joven J; Menendez JA
Cell Cycle; 2014; 13(7):1132-44. PubMed ID: 24553122
[TBL] [Abstract][Full Text] [Related]
2. The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling.
Scherbakov AM; Sorokin DV; Tatarskiy VV; Prokhorov NS; Semina SE; Berstein LM; Krasil'nikov MA
IUBMB Life; 2016 Apr; 68(4):281-92. PubMed ID: 26892736
[TBL] [Abstract][Full Text] [Related]
3. Nuclear reprogramming of luminal-like breast cancer cells generates Sox2-overexpressing cancer stem-like cellular states harboring transcriptional activation of the mTOR pathway.
Corominas-Faja B; Cufí S; Oliveras-Ferraros C; Cuyàs E; López-Bonet E; Lupu R; Alarcón T; Vellon L; Iglesias JM; Leis O; Martín ÁG; Vazquez-Martin A; Menendez JA
Cell Cycle; 2013 Sep; 12(18):3109-24. PubMed ID: 23974095
[TBL] [Abstract][Full Text] [Related]
4. Stem cell-like breast cancer cells with acquired resistance to metformin are sensitive to inhibitors of NADH-dependent CtBP dimerization.
Banerjee A; Birts CN; Darley M; Parker R; Mirnezami AH; West J; Cutress RI; Beers SA; Rose-Zerilli MJJ; Blaydes JP
Carcinogenesis; 2019 Jul; 40(7):871-882. PubMed ID: 30668646
[TBL] [Abstract][Full Text] [Related]
5. Metformin reverses multidrug resistance and epithelial-mesenchymal transition (EMT) via activating AMP-activated protein kinase (AMPK) in human breast cancer cells.
Qu C; Zhang W; Zheng G; Zhang Z; Yin J; He Z
Mol Cell Biochem; 2014 Jan; 386(1-2):63-71. PubMed ID: 24096736
[TBL] [Abstract][Full Text] [Related]
6. PYK2 promotes HER2-positive breast cancer invasion.
Al-Juboori SI; Vadakekolathu J; Idri S; Wagner S; Zafeiris D; Pearson JR; Almshayakhchi R; Caraglia M; Desiderio V; Miles AK; Boocock DJ; Ball GR; Regad T
J Exp Clin Cancer Res; 2019 May; 38(1):210. PubMed ID: 31118051
[TBL] [Abstract][Full Text] [Related]
7. Metformin against TGFβ-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis.
Cufí S; Vazquez-Martin A; Oliveras-Ferraros C; Martin-Castillo B; Joven J; Menendez JA
Cell Cycle; 2010 Nov; 9(22):4461-8. PubMed ID: 21088486
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo antiproliferative activity of metformin on stem-like cells isolated from spontaneous canine mammary carcinomas: translational implications for human tumors.
Barbieri F; Thellung S; Ratto A; Carra E; Marini V; Fucile C; Bajetto A; Pattarozzi A; Würth R; Gatti M; Campanella C; Vito G; Mattioli F; Pagano A; Daga A; Ferrari A; Florio T
BMC Cancer; 2015 Apr; 15():228. PubMed ID: 25884842
[TBL] [Abstract][Full Text] [Related]
9. Metformin is synthetically lethal with glucose withdrawal in cancer cells.
Menendez JA; Oliveras-Ferraros C; Cufí S; Corominas-Faja B; Joven J; Martin-Castillo B; Vazquez-Martin A
Cell Cycle; 2012 Aug; 11(15):2782-92. PubMed ID: 22809961
[TBL] [Abstract][Full Text] [Related]
10. Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
Kim J; Lee J; Kim C; Choi J; Kim A
Tumour Biol; 2016 May; 37(5):5811-9. PubMed ID: 26581908
[TBL] [Abstract][Full Text] [Related]
11. Metformin inhibits metastatic breast cancer progression and improves chemosensitivity by inducing vessel normalization via PDGF-B downregulation.
Wang JC; Li GY; Wang B; Han SX; Sun X; Jiang YN; Shen YW; Zhou C; Feng J; Lu SY; Liu JL; Wang MD; Liu PJ
J Exp Clin Cancer Res; 2019 Jun; 38(1):235. PubMed ID: 31164151
[TBL] [Abstract][Full Text] [Related]
12. Activation of AMP-activated protein kinase (AMPK) provides a metabolic barrier to reprogramming somatic cells into stem cells.
Vazquez-Martin A; Vellon L; Quirós PM; Cufí S; Ruiz de Galarreta E; Oliveras-Ferraros C; Martin AG; Martin-Castillo B; López-Otín C; Menendez JA
Cell Cycle; 2012 Mar; 11(5):974-89. PubMed ID: 22333578
[TBL] [Abstract][Full Text] [Related]
13. The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells.
Vazquez-Martin A; Oliveras-Ferraros C; Del Barco S; Martin-Castillo B; Menendez JA
Breast Cancer Res Treat; 2011 Apr; 126(2):355-64. PubMed ID: 20458531
[TBL] [Abstract][Full Text] [Related]
14. Metformin inhibits P-glycoprotein expression via the NF-κB pathway and CRE transcriptional activity through AMPK activation.
Kim HG; Hien TT; Han EH; Hwang YP; Choi JH; Kang KW; Kwon KI; Kim BH; Kim SK; Song GY; Jeong TC; Jeong HG
Br J Pharmacol; 2011 Mar; 162(5):1096-108. PubMed ID: 21054339
[TBL] [Abstract][Full Text] [Related]
15. [Antitumor mechanism of metformin via adenosine monophosphate-activated protein kinase (AMPK) activation].
Chen Z; Wang L; Chen Y
Zhongguo Fei Ai Za Zhi; 2013 Aug; 16(8):427-32. PubMed ID: 23945247
[TBL] [Abstract][Full Text] [Related]
16. Immune-mediated anti-tumor effects of metformin; targeting metabolic reprogramming of T cells as a new possible mechanism for anti-cancer effects of metformin.
Bahrambeigi S; Shafiei-Irannejad V
Biochem Pharmacol; 2020 Apr; 174():113787. PubMed ID: 31884044
[TBL] [Abstract][Full Text] [Related]
17. Regulation of metformin response by breast cancer associated gene 2.
Buac D; Kona FR; Seth AK; Dou QP
Neoplasia; 2013 Dec; 15(12):1379-90. PubMed ID: 24403860
[TBL] [Abstract][Full Text] [Related]
18. Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts.
Cufi S; Corominas-Faja B; Vazquez-Martin A; Oliveras-Ferraros C; Dorca J; Bosch-Barrera J; Martin-Castillo B; Menendez JA
Oncotarget; 2012 Apr; 3(4):395-8. PubMed ID: 22565037
[TBL] [Abstract][Full Text] [Related]
19. Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells.
Talarico G; Orecchioni S; Dallaglio K; Reggiani F; Mancuso P; Calleri A; Gregato G; Labanca V; Rossi T; Noonan DM; Albini A; Bertolini F
Sci Rep; 2016 Jan; 6():18673. PubMed ID: 26728433
[TBL] [Abstract][Full Text] [Related]
20. Metformin reverses mesenchymal phenotype of primary breast cancer cells through STAT3/NF-κB pathways.
Esparza-López J; Alvarado-Muñoz JF; Escobar-Arriaga E; Ulloa-Aguirre A; de Jesús Ibarra-Sánchez M
BMC Cancer; 2019 Jul; 19(1):728. PubMed ID: 31337349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
